Market Exclusive

Analyst Activity – Aegis Reiterates Buy on Heron Therapeutics (NASDAQ:HRTX)

Analyst Ratings For Heron Therapeutics (NASDAQ:HRTX)

Today, Aegis reiterated its Buy rating on Heron Therapeutics (NASDAQ:HRTX) with a price target of $33.00.

There are 10 buy ratings on the stock.

The current consensus rating on Heron Therapeutics (NASDAQ:HRTX) is Buy (Score: 3.00) with a consensus target price of $33.13 per share, a potential 104.48% upside.

Some recent analyst ratings include


Recent Trading Activity for Heron Therapeutics (NASDAQ:HRTX)
Shares of Heron Therapeutics closed the previous trading session at 16.80 up +0.60 3.70% with 1,717,997 shares trading hands.

Exit mobile version